What is the minimum investment required for PCD Pharma Franchise?

The minimum investment typically ranges from ₹2–5 lakhs, depending on territory size, product selection and initial stock planning. Our team will help structure this based on your goals.

What documents are required to become a franchise partner?

You will need a valid Drug License, GST registration and basic KYC documents. Our team will guide you through every step of the documentation process.

What kind of support and training do you provide?

We provide product training, sales guidance, marketing materials, doctor coverage strategies, and ongoing business support through dedicated account managers.

How are territories allocated and protected?

Territories are allocated based on mutual agreement and market mapping. We offer genuine monopoly rights with clear documentation to avoid internal competition.

What is the expected profit margin and ROI timeline?

Average profit margins range from 25–30%, with typical ROI timelines between 12–18 months, depending on your execution and territory potential.

How do you ensure product quality and compliance?

All products are manufactured in WHO-GMP certified facilities with 100% quality testing, robust documentation and DCGI approvals as applicable.

What is the delivery timeline and process?

Dispatch timelines depend on order size and location, but we maintain a strong track record of timely delivery across India with proper packaging and logistics partners.

Antibiotics/Anti-infectives

AXICEF-125 D/S

Cefuroxime 125 mg Dry Syrup

Pack: 30ML
Format: With Carton

MRP₹126.56

A premium second-generation cephalosporin antibacterial dry syrup designed for the effective management of acute and persistent pediatric infections. AXICEF-125 provides a high degree of stability against bacterial enzymes, ensuring rapid clinical recovery from respiratory, ear, and skin infections.

About The Product

Key Benefits

Advanced Second-Generation Antibacterial Power

Cefuroxime Axetil 125mg is a potent second-generation cephalosporin that works by inhibiting bacterial cell wall synthesis. It offers a broader spectrum of activity than first-generation antibiotics and is specifically effective against both Gram-positive and Gram-negative pathogens responsible for common childhood illnesses.

Superior Resistance to Beta-Lactamases

A key clinical advantage of AXICEF-125 is its high stability against beta-lactamase enzymes produced by resistant bacteria. This makes it a highly reliable choice for treating "tough" infections that may have failed to respond to standard amoxicillin or other primary penicillins.

Targeteddd Management of Respiratory and Ear Infections

AXICEF-125 is a gold-standard treatment for acute otitis media (middle ear infection), tonsillitis, and pharyngitis. Its excellent tissue penetration ensures that the antibiotic reaches the site of infection in therapeutic concentrations, rapidly reducing pain, swelling, and fever.

Effective Lower Respiratory Tract Support

Beyond upper respiratory care, AXICEF-125 is highly effective in treating early-stage bronchitis and community-acquired pneumonia. By clearing the bronchial tree of harmful bacteria, it helps restore normal lung function and prevents the progression of respiratory distress in children.

High Bioavailability for Faster Recovery

The dry syrup is formulated as Cefuroxime Axetil, which is an ester prodrug designed for optimal absorption in the gastrointestinal tract. Once ingested, it is rapidly converted to active Cefuroxime in the bloodstream, ensuring a fast onset of action to combat systemic infections.

Consistent and Accurate Pediatric Dosing

The 125mg/5ml concentration is clinically optimized for pediatric use. The dry syrup format ensures the stability of the antibiotic until it is reconstituted, guaranteeing that the child receives the full therapeutic potency required to clear the infection and prevent a relapse.

Indication Acute Otitis Media (Middle Ear Infection), Tonsillitis and Pharyngitis, Acute Sinusitis, Lower Respiratory Tract Infections (Bronchitis), Skin and Soft Tissue Infections, Urinary Tract Infections (UTIs).

Indications

Acute Otitis Media (Middle Ear Infection)
Tonsillitis and Pharyngitis
Acute Sinusitis
Lower Respiratory Tract Infections (Bronchitis)
Skin and Soft Tissue Infections
Urinary Tract Infections (UTIs).

Product descriptions, dosage forms, and compositions listed on the website are for reference by licensed practitioners and distributors only.

AXICEF-125 D/S